FUSEN PHARM (01652) releases interim financial results, with a shareholder's net loss of 23.136 million yuan, narrowing by 37.37% year-on-year.
Fosun Pharma (01652) announced its interim results for the six months ending June 30, 2025, with a profit of 1.11...
FUSEN PHARM(01652) released its interim results for the six months ending on June 30, 2025, with a revenue of 111 million yuan (RMB), a decrease of 43.31% compared to the same period last year. Shareholders' net loss was 23.136 million yuan, a decrease of 37.37% compared to the same period last year. Basic loss per share was 3 cents.
Related Articles
TAIZHOU WATER (01542) announced its interim results, with the attributable loss to the owners of the parent company approximately 19.875 million yuan, a year-on-year decrease of 45.21%.
.png)
CONGYU INTE AGR (00875) announced its interim results, with a net profit attributable to shareholders of HK$1.262 million, a decrease of 86.4% year-on-year.
KIDZTECH (06918) released its mid-year performance, with a net loss attributable to shareholders of 15.036 million yuan, a decrease of 14.49% year-on-year.
TAIZHOU WATER (01542) announced its interim results, with the attributable loss to the owners of the parent company approximately 19.875 million yuan, a year-on-year decrease of 45.21%.
CONGYU INTE AGR (00875) announced its interim results, with a net profit attributable to shareholders of HK$1.262 million, a decrease of 86.4% year-on-year.
KIDZTECH (06918) released its mid-year performance, with a net loss attributable to shareholders of 15.036 million yuan, a decrease of 14.49% year-on-year.
RECOMMEND
EU Proposes Legislation to Enact Transatlantic Trade Framework by Eliminating Select U.S. Tariffs and Reducing Auto Duties to 15%
29/08/2025
Six Months In, WuXi Juno’s Revenue Just Exceeds RMB 100 Million as Commercialization of High-Priced Cancer Therapy Stalls
29/08/2025
Offshore Renminbi Briefly Exceeds 7.12 for First Time in Nearly Ten Months, Future Trajectory Under Scrutiny
29/08/2025
